XERIS BIOPHARMA HOLDINGS, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $137.6M | $96.5M | $103.8M |
| Jun 2022 | $138.1M | $73.9M | $95.3M |
| Sep 2022 | $138.5M | $55.0M | $84.1M |
| Dec 2022 | $187.1M | $45.2M | $122.0M |
| Mar 2023 | $187.6M | $30.0M | $51.0M |
| Jun 2023 | $188.2M | $13.6M | $46.2M |
| Sep 2023 | $190.4M | $3.9M | $46.1M |
| Dec 2023 | $190.9M | $-6.8M | $67.4M |
| Mar 2024 | $229.7M | $-9.2M | $62.7M |
| Jun 2024 | $230.5M | $-19.3M | $57.6M |
| Sep 2024 | $216.2M | $-28.3M | $59.2M |
| Dec 2024 | $217.0M | $-29.6M | $71.6M |
| Mar 2025 | $217.8M | $-35.1M | $58.4M |
| Jun 2025 | $218.6M | $-19.3M | $59.3M |
| Sep 2025 | $219.5M | $-861.0K | $91.6M |
| Dec 2025 | $220.3M | $13.7M | $111.0M |
| Mar 2026 | $221.2M | $13.0M | $111.8M |
| Jun 2026 | $188.8M | $-9.7M | $121.7M |